221 related articles for article (PubMed ID: 32687365)
1. Design and Structural Optimization of Dual FXR/PPARδ Activators.
Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
Feng Z; Xiang J; Liu H; Li J; Xu X; Sun G; Zheng R; Zhang S; Liu J; Yang S; Xu Q; Wen X; Yuan H; Sun H; Dai L
J Med Chem; 2022 Feb; 65(3):2571-2592. PubMed ID: 35060744
[TBL] [Abstract][Full Text] [Related]
4. A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
Schmidt J; Rotter M; Weiser T; Wittmann S; Weizel L; Kaiser A; Heering J; Goebel T; Angioni C; Wurglics M; Paulke A; Geisslinger G; Kahnt A; Steinhilber D; Proschak E; Merk D
J Med Chem; 2017 Sep; 60(18):7703-7724. PubMed ID: 28845983
[TBL] [Abstract][Full Text] [Related]
5. A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice.
Heitel P; Faudone G; Helmstädter M; Schmidt J; Kaiser A; Tjaden A; Schröder M; Müller S; Schierle S; Pollinger J; Merk D
Commun Chem; 2020 Nov; 3(1):174. PubMed ID: 36703463
[TBL] [Abstract][Full Text] [Related]
6. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
[TBL] [Abstract][Full Text] [Related]
7. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
[TBL] [Abstract][Full Text] [Related]
8. Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
Maltarollo VG; Togashi M; Nascimento AS; Honorio KM
PLoS One; 2015; 10(3):e0118790. PubMed ID: 25767888
[TBL] [Abstract][Full Text] [Related]
9. Advances and Challenges in Drug Design of PPARδ Ligands.
Maltarollo VG; Kronenberger T; Windshugel B; Wrenger C; Trossini GHG; Honorio KM
Curr Drug Targets; 2018; 19(2):144-154. PubMed ID: 28413978
[TBL] [Abstract][Full Text] [Related]
10. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
11. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver.
Qiu Q; Wang W; Zhao X; Chen Y; Zhao S; Zhu J; Xu X; Geng R
Bioorg Chem; 2020 Nov; 104():104262. PubMed ID: 32919135
[TBL] [Abstract][Full Text] [Related]
13. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.
Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X
J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079
[TBL] [Abstract][Full Text] [Related]
14. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
Gohda K; Iguchi Y; Masuda A; Fujimori K; Yamashita Y; Teno N
Bioorg Med Chem Lett; 2021 Jun; 41():128026. PubMed ID: 33839252
[TBL] [Abstract][Full Text] [Related]
15. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
16. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
Hye Khan MA; Schmidt J; Stavniichuk A; Imig JD; Merk D
Biochem Pharmacol; 2019 Aug; 166():212-221. PubMed ID: 31129048
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
[TBL] [Abstract][Full Text] [Related]
18. Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators.
Schierle S; Schmidt J; Kaiser A; Merk D
ChemMedChem; 2018 Dec; 13(23):2530-2545. PubMed ID: 30353976
[TBL] [Abstract][Full Text] [Related]
19. Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast.
Schierle S; Helmstädter M; Schmidt J; Hartmann M; Horz M; Kaiser A; Weizel L; Heitel P; Proschak A; Hernandez-Olmos V; Proschak E; Merk D
ChemMedChem; 2020 Jan; 15(1):50-67. PubMed ID: 31670489
[TBL] [Abstract][Full Text] [Related]
20. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]